🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →
Business news, market intelligence, and global industry analysis.
The Latest

Divi’s Laboratories to manufacture API of MSD’s Covid drug Molnupiravir

bySrinath
May 27, 2021
Total
0
Shares
0
0
0

Divi’s Laboratories Limited has been selected by pharma giant MSD (known as Merck in the US and Canada) as an authorized manufacturer for the active pharmaceutical ingredient (API) of the latter Covid-19 drug candidate Molnupiravir.

The Hyderabad-based API producer said that it is allowed to supply Molnupiravir API to MSD’s

Currently, Molnupiravir is being evaluated in a phase 3 clinical trial. MSD is developing the drug candidate in collaboration with Ridgeback Biotherapeutics.

Divi's Laboratories to manufacture API of MSD’s Covid drug Molnupiravir
Divi’s Laboratories to manufacture API of MSD’s Covid drug Molnupiravir. Image courtesy of Pete Linforth from Pixabay.

Last month, Cipla signed a non-exclusive licensing agreement with MSD for the manufacturing and distribution of Molnupiravir for the treatment of non-hospitalized Covid-19 patients.

Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Quidel’s Lyra Direct SARS-CoV-2 Assay gets FDA EUA status for molecular detection of COVID-19

Quidel has been given emergency use authorization from the US Food and Drug Administration (FDA) for its Lyra Direct SARS-CoV-2 Assay to be used for the molecular detection of COVID-19. According to the diagnostic healthcare products manufacturer, the EUA status enables the Lyra Direct SARS-CoV-2 Assay for carrying out direct sample processing without the extraction […]
bypharmanewsdaily